Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
168 Chapter 13 · Treatment of Adult ALL According to Protocols of the German Multicenter Study Group for Adult ALL (GMALL)<br />
Table 13.1. Studies of the German Multicenter Study Group for Adult ALL<br />
Studies Period Aims Patients (~)<br />
01/81 1978–1983 Application of a modified pediatric treatment protocol in adult ALL 384<br />
13.2 Therapy for Younger (15–65 Years) Patients<br />
with B-Precursor and T-Lineage ALL<br />
13.2.1 GMALL Trials 01/81–07/03<br />
In the earlier trials (01/81–05/93), an 8-week induction<br />
therapy with two phases was scheduled with several minor<br />
modifications [1]. All patients received reinduction<br />
therapy, and maintenance therapy with methotrexate<br />
(M) and 6-mercaptopurine (MP) was scheduled for a total<br />
treatment duration of approximately 2 1/2 years. The<br />
overall treatment outline of GMALL studies 01/81–07/03<br />
is given in Fig. 13.1.<br />
Central diagnosis review (morphology/cytochemistry, immunophenotyping)<br />
02/84 1983–1987 Stratification to standard and high-risk patients<br />
Intensified consolidation therapy for high-risk patients<br />
B-NHL81 protocol for mature B-ALL<br />
569<br />
03/87 1987–1989 High-dose cytarabine/mitoxantrone as consolidation therapy<br />
in high-risk patients<br />
B-NHL84 protocol for mature B-ALL<br />
350<br />
04/89 1989–1993 Extended central diagnosis review (cytogenetics, molecular genetics)<br />
Randomized evaluation of high-dose consolidation therapy in<br />
high-risk patients<br />
Allogeneic stem cell transplantation in all high-risk patients in CR1<br />
580<br />
05/93 1993–1999 Risk-adapted, intensified consolidation therapy with 3 risk groups<br />
Randomized evaluation of conventional vs. intensified maintenance<br />
therapy<br />
Pilot study for evaluation of minimal residual disease<br />
B-NHL90 protocol for mature B-ALL and B-NHL<br />
1200<br />
06/99 1999–2003 Pilot study for GMALL 07/03 830<br />
07/03 2003–ongoing Shortened and intensified induction therapy<br />
Evaluation of a combined risk stratification according to<br />
conventional risk factors and MRD<br />
Risk-adapted postremission therapy<br />
Stem cell transplantation (allogeneic sibling, unrelated, and<br />
autologous) in high-risk and very-high-risk patients<br />
680<br />
The results of earlier trials (01/81–04/89) have been<br />
summarized previously [1–4]. Major findings referred<br />
to identification of new prognostic factors, development<br />
of subgroup-specific and risk-adapted regimens,<br />
intensified consolidation and maintenance, and extended<br />
indications for stem cell transplantation (SCT).<br />
In study 03/87 it was shown that postponed (standard<br />
risk = SR patients) or omitted (high risk = HR patients)<br />
CNS irradiation was associated with inferior overall<br />
outcome and a higher rate of CNS relapse [1]. Complete<br />
remission (CR) rates, remission duration, and<br />
survival improved stepwise with significant differences<br />
between subgroups.